Revolution Medicines Officer Files Form 144 to Sell $1.27M in Common Stock

Executive Summary

On September 29, 2026, Alan Sandler, an Officer at Revolution Medicines, Inc. (NASDAQ: RVMD), filed a Form 144 notifying the SEC of a proposed sale of 6,309 shares of common stock with an aggregate market value of approximately $1.27 million.

Transaction Details

• Filing Date: September 29, 2026
• Approximate Sale Date: September 29, 2026
• Securities Offered: 6,309 common shares
  • 6,000 shares: Acquired via stock option exercise on September 29, 2026 (paid via cash).
  • 309 shares: Acquired via restricted stock unit (RSU) vesting on September 15, 2026.
• Aggregate Market Value: $1,272,777.66 (~$201.74 per share implied)
• Shares Outstanding: 214,336,418 shares (proposed sale represents <0.01% of outstanding shares)
• Executing Broker: Morgan Stanley Smith Barney LLC Executive Financial Services

Rule 10b5-1 Plan and Prior Activity

• Trading Plan: The proposed sale is executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2026.
• Past 3 Months Activity: The insider reported a prior sale of 341 shares on September 16, 2026, for gross proceeds of $67,940.67.

Market & Trading Significance

The trading significance of this filing is assessed as Low. The transaction constitutes a negligible fraction of RVMD's total float and appears to be part of a routine liquidity plan involving stock option exercises and RSU settlements under an established 10b5-1 plan.